Clene Inc. (CLNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clene Inc. (CLNN) has a cash flow conversion efficiency ratio of 0.241x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.53 Million) by net assets ($-18.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Clene Inc. balance sheet quality to measure how much of total assets are equity-financed.
Clene Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Clene Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CLNN cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Clene Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clene Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Entera Bio Ltd
NASDAQ:ENTX
|
-0.180x |
|
Deniz Gayrimenkul Yatirim Ortakligi AS
IS:DZGYO
|
0.068x |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
0.065x |
|
Solutions 30 SE
F:30L3
|
-0.234x |
|
HLB Life Science Co. Ltd
KQ:067630
|
-0.016x |
|
Castellum Inc.
NYSE MKT:CTM
|
0.036x |
|
EuroDry Ltd
NASDAQ:EDRY
|
0.074x |
|
Titanium Oyj
HE:TITAN
|
0.222x |
Annual Cash Flow Conversion Efficiency for Clene Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Clene Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Clene Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-17.59 Million | $-18.55 Million | 1.054x | -56.22% |
| 2024-12-31 | $-8.86 Million | $-21.33 Million | 2.408x | +206.86% |
| 2023-12-31 | $13.39 Million | $-30.17 Million | -2.253x | +81.30% |
| 2022-12-31 | $3.24 Million | $-39.01 Million | -12.052x | -338.46% |
| 2021-12-31 | $12.60 Million | $-34.62 Million | -2.749x | +95.05% |
| 2020-12-31 | $341.00K | $-18.93 Million | -55.510x | -1955.61% |
| 2019-12-31 | $4.89 Million | $-13.20 Million | -2.700x | -6474.48% |
| 2018-12-31 | $5.00 Million | $-205.37K | -0.041x | -- |
About Clene Inc.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral … Read more